Treating to re-establish tolerance in inflammatory arthritis - Lessons from other diseases

Best Practice and Research: Clinical Rheumatology

Volumn 24, Issue 4, 2010, Pages 497-511

  Cooles, Faye A H ^a   Isaacs, John D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

anti CD3; autologous stem cell transplantation; cellular therapy; immune modulation; immunotherapy; mesenchymal stromal cell; mixed chimaerism; therapeutic tolerance; tolerance biomarkers; tolerogenic dendritic cell

Indexed keywords

ABATACEPT; ALEMTUZUMAB; CD3 ANTIBODY; CYCLOSPORIN; GLYCOPROTEIN GP 39; HUMAN CARTILAGE GLYCOPROTEIN 39; INFLIXIMAB; INTERLEUKIN 10; METHOTREXATE; OKT 3; OTELIXIZUMAB; RAPAMYCIN; TEPLIZUMAB; TGN 1412; THYMOCYTE ANTIBODY; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VISILIZUMAB;

ACUTE GRAFT REJECTION; ANCA ASSOCIATED VASCULITIS; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; ATOPY; AUTOIMMUNITY; AUTOLOGOUS STEM CELL TRANSPLANTATION; BEHCET DISEASE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC GRAFT REJECTION; CLINICAL TRIAL; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNE DYSREGULATION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; ULCERATIVE COLITIS; UNSPECIFIED SIDE EFFECT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; BIOLOGICAL MARKERS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; STEM CELL TRANSPLANTATION; TRANSPLANTATION TOLERANCE; TRANSPLANTATION, AUTOLOGOUS;

EID: 77956157211     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.berh.2010.01.007     Document Type: Review

References (87)

1. S. ten Wolde, F.C. Breedveld, and J. Hermans Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis Lancet 347 8998 1996 347 352
2. H. Waldmann Manipulation of T-cell responses with monoclonal antibodies Annu Rev Immunol 7 1989 407 444
3. S. Qin, S.P. Cobbold, and H. Pope "Infectious" transplantation tolerance Science 259 5097 1993 974 977
4. S.P. Cobbold, E. Adams, and S.E. Marshall Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8 Immunol Rev 149 1996 5 33
5. A. van der Helm-van Mil, F. Breedveld, and T. Huizinga Aspects of early arthritis. Definition of disease states in early arthritis: remission versus minimal disease activity Arthritis Research & Therapy 8 4 2006 216
6. H. Waldmann, and S. Cobbold How may immunosuppression lead to tolerance? The war analogy S. Plotkin, B. Fantini, Immune tolerance: Jenner, Pasteur and their successors 1997 Elsevier Paris
7. V. Strand, R. Kimberly, and J.D. Isaacs Biologic therapies in rheumatology: lessons learned, future directions Nat Rev Drug Discov 6 1 2007 75 92
8. J.D. Isaacs, R.A. Watts, and B.L. Hazleman Humanised monoclonal antibody therapy for rheumatoid arthritis Lancet 340 1992 748 752
9. J.D. Isaacs, V.K. Manna, and N. Rapson CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study Br J Rheumatol 35 3 1996 231 240
10. J.D. Isaacs, S. Greer, and S. Sharma Morbidity and mortality in rheumatoid arthritis patients with profound and prolonged therapy-induced lymphopenia Arthritis Rheum 44 2001 1998 2008
11. A.R. Lorenzi, A.M. Clarke, and T. Wooldridge Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: Twelve-year outcomes Arthritis Rheum 58 2 2008 370 375
12. R.H. Schwartz A cell culture model for T lymphocyte clonal anergy Science 248 4961 1990 1349 1356
13. M.C. Genovese, M. Schiff, and M. Luggen Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-TNF therapy Ann Rheum Dis 67 4 2008 547 554
14. S.P. Cobbold, G. Martin, and H. Waldmann The induction of skin graft tolerance in major histocompatibility complex-mismatched or primed recipients: primed T cells can be tolerized in the periphery with anti-CD4 and anti-CD8 antibodies Eur J Immunol 20 12 1990 2747 2755
15. R.Y. Calne Prope tolerance-the future of organ transplantation from the laboratory to the clinic Int Immunopharmacol 5 1 2005 163 167
16. A.D. Salama, K.L. Womer, and M.H. Sayegh Clinical transplantation tolerance: many rivers to cross J Immunol 178 9 2007 5419 5423
17. T. Fehr, and M. Sykes Clinical experience with mixed chimerism to induce transplantation tolerance Transpl Int 21 12 2008 1118 1135
18. L.A. Turka, and R.I. Lechler Towards the identification of biomarkers of transplantation tolerance Nat Rev Immunol 9 7 2009 521 526
19. A.W. Morgan, G. Hale, and P.R.U.B. Rebello A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis Quarterly Journal of Medicine 101 4 2008 299 306
20. W.-F. Ng, and J.D. Isaacs From mice to men: the challenges of developing tolerance-inducing biological drugs for the clinic L. Graca, The Immune Synapse as a Novel Target for Therapy 2008 Birkhauser Verlag AG Basle - Boston - Berlin 169 185
21. S.T. Smiley, V. Csizmadia, and W. Gao Differential effects of cyclosporine A, methylprednisolone, mycophenolate, and rapamycin on CD154 induction and requirement for NFkappaB: implications for tolerance induction Transplantation 70 3 2000 415 419
22. J.J. Coenen, H.J. Koenen, and E. van Rijssen Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells Blood 107 3 2006 1018 1023
23. A. Valle, T. Jofra, and A. Stabilini Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice Diabetes 58 4 2009 875 881
24. L. Chatenoud, C. Ferran, and J.F. Bach The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation Curr Top Microbiol Immunol 174 1991 121 134
25. L. Chatenoud CD3-specific antibody-induced active tolerance: from bench to bedside Nat Rev Immunol 3 2 2003 123 132
26. L. Chatenoud CD3-specific antibodies restore self-tolerance: mechanisms and clinical applications Curr Opin Immunol 17 6 2005 632 637
27. K.C. Herold, W. Hagopian, and J.A. Auger Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus N Engl J Med 346 22 2002 1692 1698
28. B. Keymeulen, E. Vandemeulebroucke, and A.G. Ziegler Insulin Needs after CD3-Antibody Therapy in New-Onset Type 1 Diabetes New Engl J Med 352 2005 2598 2608
29. K.C. Herold, S.E. Gitelman, and U. Masharani A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes Diabetes 54 6 2005 1763 1769
30. K.C. Herold, S. Gitelman, and C. Greenbaum Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years Clin Immunol 132 2 2009 166 173
31. M.M. Nielen, D. van Schaardenburg, and H.W. Reesink Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors Arthritis Rheum 50 2 2004 380 386
32. K.C. Herold, J.B. Burton, and F. Francois Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala) J Clin Invest 111 3 2003 409 418
33. B. Bisikirska, J. Colgan, and J. Luban TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs J Clin Invest 115 10 2005 2904 2913
34. S. Cernea, and K.C. Herold Monitoring of antigen-specific CD8 T cells in patients with type 1 diabetes treated with antiCD3 monoclonal antibodies Clin Immunol 134 2 2010 Feb 121 129
35. D. Bresson, L. Togher, and E. Rodrigo Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs J Clin Invest 116 5 2006 1371 1381
36. G. Suntharalingam, M.R. Perry, and S. Ward Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412 N Engl J Med 355 10 2006 1018 1028
37. R. Stebbings, L. Findlay, and C. Edwards Cytokine Storm' in the Phase I Trial of Monoclonal Antibody TGN1412: Better Understanding the Causes to Improve PreClinical Testing of Immunotherapeutics J Immunol 179 5 2007 3325 3331
38. T. Moreau, A. Coles, and M. Wing Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis Brain 119 1996 225 237
39. H. Albert, M. Collin, and D. Dudziak In vivo enzymatic modulation of IgG glycosylation inhibits autoimmune disease in an IgG subclass-dependent manner Proc Natl Acad Sci U S A 105 39 2008 15005 15009
40. S. Plevy, B. Salzberg, and G. Van Assche A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis Gastroenterology 133 5 2007 1414 1422
41. A.J. Coles, D.A. Compston, and K.W. Selmaj Alemtuzumab vs. interferon beta-1a in early multiple sclerosis N Engl J Med 359 17 2008 1786 1801
42. A.J. Coles, M. Wing, and S. Smith Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis Lancet 354 9191 1999 1691 1695
43. M. Walsh, A. Chaudhry, and D. Jayne Long-term follow-up of relapsing/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H) Ann Rheum Dis 67 9 2008 1322 1327
44. C.M. Lockwood, G. Hale, and H. Waldman Remission induction in Behcet's disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H Rheumatology (Oxford) 42 12 2003 1539 1544
45. A.D. Kirk, D.A. Hale, and S.J. Swanson Autoimmune thyroid disease after renal transplantation using depletional induction with alemtuzumab Am J Transplant 6 5 Pt 1 2006 1084 1085
46. T. Daikeler, and A. Tyndall Autoimmunity following haematopoietic stem-cell transplantation Best Pract Res Clin Haematol 20 2 2007 349 360
47. J.L. Jones, C.L. Phuah, and A.L. Cox IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H) J Clin Invest 119 7 2009 2052 2061
48. M. Noris, F. Casiraghi, and M. Todeschini Regulatory T cells and T cell depletion: role of immunosuppressive drugs J Am Soc Nephrol 18 3 2007 1007 1018
49. D. Valmori, V. Tosello, and N.E. Souleimanian Rapamycin-mediated enrichment of T cells with regulatory activity in stimulated CD4+ T cell cultures is not due to the selective expansion of naturally occurring regulatory T cells but to the induction of regulatory functions in conventional CD4+ T cells J Immunol 177 2 2006 944 949
50. M. Battaglia, A. Stabilini, and B. Migliavacca Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients J Immunol 177 12 2006 8338 8347
51. P. Ruggenenti, N. Perico, and E. Gotti Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury Transplantation 84 8 2007 956 964
52. C. Alexander, M. Tarzi, and M. Larche The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects Allergy 60 10 2005 1269 1274
53. A. Verhoef, C. Alexander, and A.B. Kay T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity PLoS Med 2 3 2005 e78
54. J.D. Campbell, K.F. Buckland, and S.J. McMillan Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression J Exp Med 206 7 2009 1535 1547
55. R. Eldor, S. Kassem, and I. Raz Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results Diabetes Metab Res Rev 25 4 2009 316 320
56. M. Massa, M. Passalia, and S.M. Manzoni Differential recognition of heat-shock protein dnaJ-derived epitopes by effector and Treg cells leads to modulation of inflammation in juvenile idiopathic arthritis Arthritis Rheum 56 5 2007 1648 1657
57. H. de Jong, F.F. Lafeber, and W. de Jager Pan-DR-binding Hsp60 self epitopes induce an interleukin-10-mediated immune response in rheumatoid arthritis Arthritis Rheum 60 7 2009 1966 1976
58. G. Nussbaum, A. Zanin-Zhorov, and F. Quintana Peptide p277 of HSP60 signals T cells: inhibition of inflammatory chemotaxis Int Immunol 18 10 2006 1413 1419
59. B. Bielekova, B. Goodwin, and N. Richert Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand Nat Med 6 10 2000 1167 1175
60. R.B. Landewe, J.G. Houbiers, and F.E. Van den Bosch Intranasal administration of recombinant Human Cartilage glycoprotein-39 as a treatment for rheumatoid arthritis: A Phase II, multicenter, double-blind, randomized, placebo-controlled, parallel group dose-finding trial Ann Rheum Dis 2009
61. D. Jones Retuning the immune system: the future of type 1 diabetes therapy? Nat Rev Drug Discov 8 8 2009 600 601
62. J.A. Snowden, J. Passweg, and J.J. Moore Autologous hemopoietic stem cell transplantation in severe rheumatoid arthritis: a report from the EBMT and ABMTR J Rheumatol 31 3 2004 482 488
63. I. de Kleer, B. Vastert, and M. Klein Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autoreactive T cells and restoring the CD4+CD25+ immune regulatory network Blood 107 4 2006 1696 1702
64. D.M. Brinkman, I.M. de Kleer, and R. ten Cate Autologous stem cell transplantation in children with severe progressive systemic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial Arthritis Rheum 56 7 2007 2410 2421
65. T. Alexander, A. Thiel, and O. Rosen Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system Blood 113 1 2009 214 223
66. P.A. Muraro, D.C. Douek, and A. Packer Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients J Exp Med 201 5 2005 805 816
67. R.J. Verburg, R. Flierman, and J.K. Sont Outcome of intensive immunosuppression and autologous stem cell transplantation in patients with severe rheumatoid arthritis is associated with the composition of synovial T cell infiltration Ann Rheum Dis 64 10 2005 1397 1405
68. F. Ponchel, A.W. Morgan, and S.J. Bingham Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis Blood 100 2002 4550 4556
69. F. Ponchel, R.J. Verburg, and S.J. Bingham Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia Arthritis Res Ther 7 2005 R80 92
70. M.R. Ehrenstein, J.G. Evans, and A. Singh Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy J Exp Med 200 2004 277 285
71. J. Samuels, Y.S. Ng, and C. Coupillaud Impaired early B cell tolerance in patients with rheumatoid arthritis J Exp Med 201 10 2005 1659 1667
72. S.Z. Pavletic Nonmyeloablative allogeneic hematopoietic stem cell transplantation for autoimmune disease Arthritis Rheum 50 8 2004 2387 2390
73. R. Seggewiss, and H. Einsele Hematopoietic growth factors including keratinocyte growth factor in allogeneic and autologous stem cell transplantation Semin Hematol 44 3 2007 203 211
74. E.L. Masteller, M.R. Warner, and Q. Tang Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice J Immunol 175 5 2005 3053 3059
75. Q. Tang, K.J. Henriksen, and M. Bi In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes Journal of Experimental Medicine 199 2004 1455 1465
76. E.N. Huter, G.H. Stummvoll, and R.J. DiPaolo Cutting edge: antigen-specific TGF beta-induced regulatory T cells suppress Th17-mediated autoimmune disease J Immunol 181 12 2008 8209 8213
77. C.M. Hilkens, J.D. Isaacs, and A.W. Thomson Development of dendritic cell-based immunotherapy for autoimmunity International Reviews of Immunology 29 2010 156 183
78. M.E. Bernardo, F. Locatelli, and W.E. Fibbe Mesenchymal stromal cells Ann N Y Acad Sci 1176 2009 101 117
79. A. Curti, S. Trabanelli, and V. Salvestrini The role of indoleamine 2,3-dioxygenase in the induction of immune tolerance: focus on hematology Blood 113 11 2009 2394 2401
80. E. Gonzalez-Rey, M.A. Gonzalez, and N. Varela Human adipose-derived mesenchymal stem cells reduce inflammatory and T-cell responses and induce regulatory T cells in vitro in rheumatoid arthritis Ann Rheum Dis 2009
81. M.A. Gonzalez, E. Gonzalez-Rey, and L. Rico Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells Arthritis Rheum 60 4 2009 1006 1019
82. K. Le Blanc, F. Frassoni, and L. Ball Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study Lancet 371 9624 2008 1579 1586
83. S.M. Richardson, J.A. Hoyland, and R. Mobasheri Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering Journal of Cell Physiology 222 2010 23 32
84. H. van Dongen, J. van Aken, and L.R. Lard Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial Arthritis Rheum 56 5 2007 1424 1432
85. P. Emery, P. Durez, and M. Dougados The impact of T-cell co-stimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept Ann Rheum Dis 69 3 2010 p510 p516
86. M.A. Quinn, P.G. Conaghan, and P.J. O'Connor Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomised, double-blind, placebo-controlled trial Arth Rheum 52 2005 27 35
87. S. Nadkarni, C. Mauri, and M.R. Ehrenstein Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta J Exp Med 204 1 2007 33 39